Monday, 25 June 2018

MS in the courtroom

We have made the case in the past that one of the ways healthcare professionals will begin to treat MS more actively is via the courts. In the meeting below we will be presenting a hypothetical case scenario of a patient who lost brain due to a delay in diagnosis and a delay in accessing a highly effective treatment. The consequences for this individual were profound and he is now suing the NHS and his neurologist for loss of earnings. 

The main purpose of the meeting is to review the evidence for treating MS early and effectively, i.e. applying all the management and treatment principles captured in our 'Brain Health: Time Matters in MS' policy document. The real value of this meeting for HCPs is not DrK and myself discussing the scientific or medical rationale for this strategy, but the legal perspective, in particular, the variance is MSology practice. When do you become an outlier, either an under-treater or an over-treater, and when do you expose yourself to a legal challenge from your patients?

If you are a card-carrying HCP you are welcome to attend. Due to ABPI rules, MSers can't attend.  Tickets are limited and are being allocated on a first come first serve basis.  


THE EMBEDDED INVITATION HAS HAD TO BE REMOVED AS IT IS FOR HEALTH CARE PROFESSIONAL EYES ONLY. 

IT IS  QUITE AMAZING BUT THE ABPI GUIDELINES DON'T ALLOW PHARMA TO COMMUNICATE WITH PEOPLE WHO HAVE MS DIRECTLY. 

IF YOU ARE AN HCP AND NEED MORE INFORMATION PLEASE CONTACT ME BY EMAIL. THANK YOU.

ProfG    

2 comments:

  1. Great idea. Pity MSers can't come along; this issue is as relevant to them as it is to HCPs.

    ReplyDelete
  2. It would also be useful if my Barrister could attend. I am currently suing an out of hours GP for a breech of duty of care of a co-morbidity which led to the my EDSS score of my progressive MS changing from 3.5 to 6 in approximately 1 month. This matter will likely be tested in a courtroom.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.